Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05214963 · ClinicalTrials.gov registry record · NA
Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS
A NA study, sponsored by Noctrix Health.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT05214963: Completed NA study, sponsored by Noctrix Health.
NCT05214963 is a NA study that has completed, run by Noctrix Health. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05214963, a NA study, has completed, sponsored by Noctrix Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
Prospective multi-site randomized sham-controlled study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS) who are either medication-naive or medication-refractory.
Primary Outcome
Percentage of subjects who withdraw from study citing lack of tolerability of the study device as the primary reason for withdrawal
Interventions
- DEVICE NTX100 Neuromodulation System - Active
- DEVICE NTX100 Neuromodulation System - Sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2023-10-24 |
| Phase | NA |
What the finished NCT05214963 record still lists
NCT05214963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which NTX100 Neuromodulation System - Active is the first listed.
NCT05214963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05214963 about?
NCT05214963 is a clinical study titled "Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS". Prospective multi-site randomized sham-controlled study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS) who are either medication-naive or medication-refractory.
What is the current status of trial NCT05214963?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2022-03-08. Estimated completion is 2023-10-24.
What interventions are being tested in trial NCT05214963?
The interventions under investigation include: NTX100 Neuromodulation System - Active (DEVICE), NTX100 Neuromodulation System - Sham (DEVICE).
Who is sponsoring clinical trial NCT05214963?
This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05214963's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI